FDA Approves First Therapy for Rare, Debilitating Tumor
August 5th 2019Pexidartinib (Turalio, Daiichi Sankyo) is indicated for adult patients with symptomatic tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to improvement with surgery.
Read More
New Congress Offers Expert Evaluation of Latest Neurology Trends
August 3rd 2019The 1st annual International Congress on the Future of Neurology will be held on September 27-28, 2019 in New York City, featuring a rigourous agenda of presentations, question and answer sessions, and lightning rounds highlighting topics across the breadth of neurology.
Read More
Future of Neurology Congress to Highlight New Data, Best Practices
August 3rd 2019The 1st annual International Congress on the Future of Neurology will be held on September 27-28, 2019 in New York City, featuring a rigorous agenda of presentations, question and answer sessions, and lightning rounds highlighting topics across the breadth of neurology.
Read More
FDA Approves First Therapy for Adults with Rare TGCT
August 2nd 2019Officials with the FDA have granted approval to pexidartinib (Turalio, Daiichi Sankyo) capsules for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not responsive to improvement with surgery.
Read More
Importation Plan Aims to Lower US Prescription Drug Prices Amid Safety Concerns
August 1st 2019Announced by the HHS and FDA, the plan seeks to safely import medications that would provide a cost savings to consumers, but some pharmacy and other health care professionals have expressed concerns.
Read More
Topical Treatment Options Expanded for Adolescents with Plaque Psoriasis
August 1st 2019Officials with the FDA have taken action on LEO Pharma’s calcipotriene and betamethasone dipropionate foam and topical suspension products for the topical treatment of plaque psoriasis in patients age 12 years and older.
Read More
Abemaciclib Improves Survival in Women with HR+, HER2- Advanced Breast Cancer
July 31st 2019Abemaciclib (Verzenio, Eli Lilly) in combination with fulvestrant demonstrated a statistically significant improvement in overall survival among women with metastatic breast cancer previously treated with endocrine therapy.
Read More
Proposal to Cut 340B Reimbursement Elicits Opposition From Health System Pharmacists
July 31st 2019The American Society of Health-System Pharmacists (ASHP) has released a statement opposing the Centers for Medicare and Medicaid Services’ (CMS) proposed cuts to reimbursement for drug purchased through the 340B Drug Pricing Program.
Read More